Immphentiv (Phenylephrine HCl) Patent Expiration, LOE Window & CMS Spending

Immphentiv (Phenylephrine HCl) by Hikma Pharmaceuticals: FDA Orange Book LOE 2036-09-26, 0 AB generics, $607K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN203826 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-09-26
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$607K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$607K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.